Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products.
Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling the drug-resistant bacteria that are at the centre of a global healthcare crisis.
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.
Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.
Feldan Bio Inc. is a recombinant protein company based in Quebec, Canada, specializing in the discovery, development, manufacture, and marketing of recombinant proteins and molecular biology reagents for life science companies and research laboratories globally. The company has developed the Feldan Shuttle, a patented protein-based technology platform that facilitates the delivery of transcription factors and genome editing tools for clinical applications. Feldan Bio offers a wide range of products, including monoclonal antibodies, cell culture supplements, transfection reagents, and various growth factors and enzymes. Additionally, it provides research protein products and custom services such as protein expression, antibody generation, and custom peptide synthesis. The company also develops and licenses therapeutic proteins aimed at biopharmaceutical companies focusing on treatments for diseases like cancer and diabetes. Founded in 1999, Feldan Bio is committed to advancing therapeutic applications through its innovative technology platform.
SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.
Peptilogics is developing eCAP technology, a propriety platform with preclinical effectiveness against resistant bacteria and biofilms. The company is dedicated to developing a new class of broad-spectrum antibiotics to address the epidemic of multidrug-resistant bacterial infections.
Peptilogics is a preclinical biotechnology company with demonstrated preclinical in vitro and in vivo effectiness against the priority resistant pathogens.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
EnBiotix, Inc. is a biotechnology company focused on developing and commercializing innovative products for chronic and recurrent pulmonary infections, as well as other diseases. The company employs advanced synthetic biology and systems biology platforms to enhance the efficacy of existing antibiotics and address the growing challenge of drug-resistant bacterial infections. EnBiotix's product pipeline includes promising candidates such as EBX-001 for Pseudomonas aeruginosa infections in cystic fibrosis patients, EBX-002 for catheter-associated urinary tract infections, and EPP-001 for prosthetic joint infections. Founded in 2010 and based in Boston, Massachusetts, EnBiotix aims to significantly improve treatment options for patients facing life-threatening infections in a market that exceeds $40 billion.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease. The company was founded in 2005 and is based in Marina del Rey, CA, USA.
Hunterian Medicine is a biotech company that develops cures for a vast number of genetic diseases where no FDA approved therapies exist. It is poised to unleash the full potential of CRISPR. Its patented platform technology solves the CRISPR delivery problem by enabling efficient, on-target delivery through a single adeno-associated virus (AAV). The Company was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Splisense
Series B in 2021
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Microbion Corporation is a biopharmaceutical company dedicated to developing therapeutics for difficult-to-treat infections, particularly those caused by antibiotic-resistant bacteria. Founded in 1982 and headquartered in Bozeman, Montana, with an office in Vancouver, Canada, the company specializes in bismuth-thiols to address chronic and acute wound infections, post-surgical orthopedic infections, and to manage microbial biofilms associated with medical devices. Microbion's products aim to prevent microbial biofilms from forming on implanted devices and are designed to treat conditions such as diabetic foot ulcers and orthopedic implant-related infections. Additionally, the company focuses on reducing infections associated with military wounds.
Kinnear Pharmaceuticals is a preclinical stage pharmaceutical company committed to the discovery, development and commercialization of ceragenin-based anti-infective and anti-inflammatory product candidates for diseases with large unmet clinical needs.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs aimed at addressing significant unmet medical needs in oncology and severe respiratory diseases. The company is advancing several drug candidates, including Balixafortide, an antagonist of the chemokine receptor CXCR4, which is in Phase III clinical trials for combination treatment in cancer. Other notable candidates include POL6014, an inhaled inhibitor of neutrophil elastase currently in Phase Ib trials for cystic fibrosis, and POL7306, which targets multidrug-resistant Gram-negative bacteria. Additionally, Spexis is developing inhaled murepavadin, a precision antibiotic designed to combat infections caused by Pseudomonas aeruginosa. Since its founding in 1996, Spexis has been committed to addressing the challenges of antibiotic resistance and improving treatment options for severe respiratory conditions.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.
enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.
Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.
4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.
Microbion Corporation is a biopharmaceutical company dedicated to developing therapeutics for difficult-to-treat infections, particularly those caused by antibiotic-resistant bacteria. Founded in 1982 and headquartered in Bozeman, Montana, with an office in Vancouver, Canada, the company specializes in bismuth-thiols to address chronic and acute wound infections, post-surgical orthopedic infections, and to manage microbial biofilms associated with medical devices. Microbion's products aim to prevent microbial biofilms from forming on implanted devices and are designed to treat conditions such as diabetic foot ulcers and orthopedic implant-related infections. Additionally, the company focuses on reducing infections associated with military wounds.
Crestone is a clinical stage biopharmaceutical company dedicated to developing small molecule drugs targeting serious bacterial infections. The firm utilizes a unique platform to create novel mechanisms of action, addressing significant unmet medical needs in the healthcare sector. By focusing on innovative drug development, Crestone aims to assist medical professionals in overcoming challenges related to bacterial growth and resistance, ultimately enhancing treatment outcomes for patients.
Laurent Pharmaceuticals Inc. is a Montreal-based biopharmaceutical company focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in patients with cystic fibrosis. Founded in 2012, the company is advancing a clinical-stage drug candidate known as LAU-7b, which is a novel once-a-day oral formulation of fenretinide. This drug addresses the compromised immune-inflammatory response associated with cystic fibrosis, a condition that significantly impacts pulmonary function. Laurent Pharmaceuticals aims to provide healthcare providers with a new treatment paradigm that resolves inflammation without inducing immunosuppression, targeting severe inflammatory and fibrotic diseases through its innovative lipid modulation approach.
Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
Talee Bio is a rapidly growing gene therapy company developing the next generation treatment and cures for cystic fibrosis.
Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.
Laurent Pharmaceuticals Inc. is a Montreal-based biopharmaceutical company focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in patients with cystic fibrosis. Founded in 2012, the company is advancing a clinical-stage drug candidate known as LAU-7b, which is a novel once-a-day oral formulation of fenretinide. This drug addresses the compromised immune-inflammatory response associated with cystic fibrosis, a condition that significantly impacts pulmonary function. Laurent Pharmaceuticals aims to provide healthcare providers with a new treatment paradigm that resolves inflammation without inducing immunosuppression, targeting severe inflammatory and fibrotic diseases through its innovative lipid modulation approach.
Icagen, Inc. is a biopharmaceutical company based in Durham, North Carolina, specializing in drug discovery with a focus on neuroscience and rare diseases. Founded in 2003, the company collaborates with pharmaceutical and biotechnology firms to support the development of novel small molecule drugs that target ion channels, among other therapeutic areas. Icagen offers a range of pre-clinical drug discovery services, including assay development, cell line generation, and high-throughput screening, aimed at facilitating the discovery of new therapeutics. The company's pipeline includes ICA-105665, currently in Phase I studies for epilepsy and neuropathic pain, and Senicapoc, which is in Phase I trials for asthma. Icagen has established partnerships with leading companies such as Bristol-Myers Squibb, Astellas Pharma, and Pfizer to enhance its research and development capabilities.
Laurent Pharmaceuticals Inc. is a Montreal-based biopharmaceutical company focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in patients with cystic fibrosis. Founded in 2012, the company is advancing a clinical-stage drug candidate known as LAU-7b, which is a novel once-a-day oral formulation of fenretinide. This drug addresses the compromised immune-inflammatory response associated with cystic fibrosis, a condition that significantly impacts pulmonary function. Laurent Pharmaceuticals aims to provide healthcare providers with a new treatment paradigm that resolves inflammation without inducing immunosuppression, targeting severe inflammatory and fibrotic diseases through its innovative lipid modulation approach.
Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.
Savara Inc. is a biopharmaceutical company based in Austin, Texas, specializing in rare respiratory diseases. Its primary product candidate, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Additionally, Molgradex is being evaluated in Phase IIa trials for nontuberculous mycobacterial (NTM) lung infections and cystic fibrosis patients with chronic NTM infections. Savara is also developing AeroVanc, an inhaled vancomycin, which is in Phase III trials for treating methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The company aims to expand its pipeline through strategic partnerships and product acquisitions, including a recent acquisition of a combination antibiotic that targets drug-resistant pathogens. Savara's management team has extensive experience in orphan drug development and is focused on addressing unmet medical needs in the field of pulmonary medicine.
4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.
Sound Pharmaceuticals is a biopharmaceutical company that develops prescription drugs that enable doctors and patients to prevent and treat hearing loss. It focuses on developing drug treatments for sensorineural hearing loss.
Laurent Pharmaceuticals Inc. is a Montreal-based biopharmaceutical company focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in patients with cystic fibrosis. Founded in 2012, the company is advancing a clinical-stage drug candidate known as LAU-7b, which is a novel once-a-day oral formulation of fenretinide. This drug addresses the compromised immune-inflammatory response associated with cystic fibrosis, a condition that significantly impacts pulmonary function. Laurent Pharmaceuticals aims to provide healthcare providers with a new treatment paradigm that resolves inflammation without inducing immunosuppression, targeting severe inflammatory and fibrotic diseases through its innovative lipid modulation approach.
Laurent Pharmaceuticals Inc. is a Montreal-based biopharmaceutical company focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in patients with cystic fibrosis. Founded in 2012, the company is advancing a clinical-stage drug candidate known as LAU-7b, which is a novel once-a-day oral formulation of fenretinide. This drug addresses the compromised immune-inflammatory response associated with cystic fibrosis, a condition that significantly impacts pulmonary function. Laurent Pharmaceuticals aims to provide healthcare providers with a new treatment paradigm that resolves inflammation without inducing immunosuppression, targeting severe inflammatory and fibrotic diseases through its innovative lipid modulation approach.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, specializing in the development and commercialization of therapeutics for rare and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a synthetic oral cannabinoid receptor type 2 (CB2) agonist currently in Phase III trials for systemic sclerosis and dermatomyositis, as well as Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition, Corbus is advancing CRB-4001, a peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonist, targeting conditions such as nonalcoholic steatohepatitis (NASH). Corbus has established a licensing agreement with Jenrin Discovery, LLC, to develop a library of over 600 compounds, and maintains a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for lenabasum's development in Japan. The company was founded in 2009 and demonstrates a commitment to addressing unmet medical needs in its focused therapeutic areas.
Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. In the eye and in the lung, our layer of protective mucus plays an important role in keeping our bodies healthy. Sometimes though, either through genetics, aging or environmental stimulus, our innate mucosal defense system can become compromised. Parion’s science driven technologies target respiratory and ocular diseases in which the patient’s ability to protect their mucosal surfaces is compromised
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Altus Pharmaceuticals is an information technology consulting firm that serves a diverse range of clients, including healthcare providers, manufacturing companies, and financial institutions. The firm positions itself as a strategic partner, providing expertise to help organizations navigate complex challenges and enhance their operational efficiency. With a focus on delivering impactful solutions, Altus aims to support its clients in achieving their goals while addressing the unique demands of their respective industries.